Uli Hacksell Is The CEO, President & Director of Medivir AB (publ) (STO:MVIR B) And They Just Spent kr291k On Shares
Even if it's not a huge purchase, we think it was good to see that Uli Hacksell, the CEO, President & Director of Medivir AB (publ) (STO:MVIR B) recently shelled out kr291k to buy stock, at kr14.53 per share. Even though that isn't a massive buy, it did increase their holding by 69%, which is a arguably a good sign.
Check out our latest analysis for Medivir
Medivir Insider Transactions Over The Last Year
While no particular insider transaction stood out, we can still look at the overall trading.
While Medivir insiders bought shares last year, they didn't sell. They paid about kr13.78 on average. It's great to see insiders putting their own cash into the company's stock, albeit at below the recent share price (kr14.80). You can see the insider transactions (by individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).
Insider Ownership of Medivir
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. From looking at our data, insiders own kr17m worth of Medivir stock, about 4.8% of the company. We prefer to see high levels of insider ownership.
So What Do The Medivir Insider Transactions Indicate?
The recent insider purchases are heartening. And an analysis of the transactions over the last year also gives us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. Given that insiders also own a fair bit of Medivir we think they are probably pretty confident of a bright future. Therefore, you should should definitely take a look at this FREE report showing analyst forecasts for Medivir.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
